The company is developing metallo-organic compounds that utilize the histone reductase mechanism to treat cancer. Their main product, toroglobulin, is designed to target cancer cells and provide a potential alternative to traditional cancer treatments. Garnett Mckeen Lab aims to contribute to the advancement of cancer treatment through their innovative drug development efforts.